+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

  • ID: 5157428
  • Report
  • September 2020
  • Region: Global
  • 160 Pages
  • Markets and Markets
The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

FEATURED COMPANIES

  • 3M Group
  • Anterogen Co., Ltd.
  • Bluebird Bio
  • Medipost Co., Ltd.
  • Misonix
  • Orthocell Ltd.
  • MORE

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World - 12%

List of Companies Profiled in the Report:

  • 3M (US)
  • Allergan plc (Ireland)
  • Amgen, Inc. (US)
  • Aspect Biosystems (Canada)
  • bluebird bio (US)
  • Kite Pharma (US)
  • Integra LifeSciences Holdings Corporation (US)
  • MEDIPOST Co., Ltd. (South Korea)
  • Medtronic plc (Ireland)
  • Anterogen Co., Ltd. (South Korea)
  • MiMedx Group (US)
  • Misonix (US)
  • Novartis AG (Switzerland)
  • Organogenesis Inc. (US)
  • Orthocell Limited (Australia)
  • Corestem, Inc. (South Korea)
  • Spark Therapeutics (US)
  • APAC Biotech (India)
  • Shenzhen Sibiono GeneTech Co., Ltd. (China)
  • Smith & Nephew plc (UK)
  • Stryker Corporation (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Tego Science (South Korea)
  • Vericel Corporation (US)
  • Zimmer Biomet (US)

Research Coverage:

This report provides a detailed picture of the global regenerative medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Group
  • Anterogen Co., Ltd.
  • Bluebird Bio
  • Medipost Co., Ltd.
  • Misonix
  • Orthocell Ltd.
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
Figure 1 Inclusions & Exclusions
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
1.6 Report Comparison with the March 2019 Edition
1.6.1 Summary of Changes
1.6.2 Limitations of the Current Edition

2 Research Methodology
2.1 Research Data
Figure 2 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
Figure 3 Breakdown of Primary Interviews: by Company Type, Designation, and Region
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
Figure 4 Regenerative Medicine Market: Bottom-Up Approach
2.2.2 Top-Down Approach
Figure 5 Regenerative Medicine Market: Top-Down Approach
2.3 Market Breakdown and Data Triangulation
Figure 6 Data Triangulation Methodology
2.4 Assumptions for the Study

3 Executive Summary
Figure 7 Regenerative Medicine Market, by Product, 2020 Vs. 2025 (USD Million)
Figure 8 Regenerative Medicine Market, by Application, 2020 Vs. 2025 (USD Million)
Figure 9 Regenerative Medicine Market, by Region, 2020 Vs. 2025 (USD Million)

4 Premium Insights
4.1 Regenerative Medicine Market Overview
Figure 10 Growing Investments in Regenerative Medicine Research to Drive Market Growth During the Forecast Period
4.2 Cell Therapies Market, by Type, 2020 Vs. 2025 (USD Million)
Figure 11 Autologous Cell Therapies to Dominate the Regenerative Medicine Market in the Forecast Period
4.3 Regenerative Medicine Market Share, by Application, 2020 Vs. 2025
Figure 12 Musculoskeletal Disorders is the Largest Application Segment of the Regenerative Medicine Market
4.4 Regenerative Medicine Market, by Region, 2020−2025
Figure 13 North America to Register the Highest Growth Rate During the Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 14 Regenerative Medicine Market: Drivers, Restraints, and Opportunities
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
Figure 15 Incidence of Diabetes, by Region, 2015 Vs. 2040 (Million Cases)
Table 1 Cancer Incidence and Mortality, by Region, 2012-2035
Table 2 Obesity-Associated Death Rate (%), by Country, 2017
5.2.1.2 Rising Investments in Regenerative Medicine Research
Table 3 Total Funding, by Source Type, 2016-2019 (USD Million)
Table 4 Funding from Corporate Partnerships, 2018-2019 (USD Million)
Table 5 Fundraising Through Public Offerings (Ipo & Follow-Ons), 2018-2019 (USD Million)
Table 6 Funding for Regenerative Medicine Research by the Nih Under the 21St Century Cures Act, 2017-2019 (USD Billion)
Table 7 California Institute of Regenerative Medicine Funding for Regenerative Medicine Research (2017)
5.2.1.3 Growing Pipeline of Regenerative Medicine Products
Table 8 Number of Companies Operating in the Regenerative Medicine Market, by Region, 2016-2018
Table 9 Number of Clinical Trials in the Regenerative Medicine Market, by Clinical Phase, 2018 Vs. 2019
Table 10 Number of M&A Transactions, 2016-2019 (USD Million)
5.2.2 Restraints
5.2.2.1 Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
5.2.2.2 High Cost of Cell and Gene Therapies
5.2.3 Opportunities
5.2.3.1 Implementation of the 21st Century Cures Act
5.2.3.2 Rising Demand for Organ Transplantations
5.3 Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

6 Regenerative Medicine Market, by Product
6.1 Introduction
Table 11 Funding for Regenerative Medicine Products, 2019 (USD Billion)
Table 12 Number of Clinical Trials in the Regenerative Medicine Market, 2018 Vs. 2019
Table 13 New Product Approvals in the Regenerative Medicine Market, 2018-2020
Table 14 Regenerative Medicine Market: Product Pipeline (2019)
Table 15 Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
6.2 Tissue-Engineered Products
6.2.1 Rising Prevalence of Chronic Wounds to Drive the Market Growth
Table 16 Examples of Commercialized Tissue-Engineered Products
Table 17 Tissue-Engineered Products Market, by Region, 2018-2025 (USD Million)
Table 18 North America: Tissue-Engineered Products Market, by Country, 2018-2025 (USD Million)
Table 19 Europe: Tissue-Engineered Products Market, by Country, 2018-2025 (USD Million)
Table 20 APAC: Tissue-Engineered Products Market, by Country, 2018-2025 (USD Million)
6.3 Cell Therapies
Table 21 Commercialized Cell Therapies Available in the Market
Table 22 Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 23 Cell Therapies Market, by Region, 2018-2025 (USD Million)
Table 24 North America: Cell Therapies Market, by Country, 2018-2025 (USD Million)
Table 25 Europe: Cell Therapies Market, by Country, 2018-2025 (USD Million)
Table 26 APAC: Cell Therapies Market, by Country, 2018-2025 (USD Million)
6.3.1 Autologous Therapies
6.3.1.1 Autologous Therapies Segment to Register the Highest Growth in the Cell Therapies Market
Table 27 Examples of Commercialized Autologous Cell Therapies
Table 28 Autologous Therapies Market, by Region, 2018-2025 (USD Million)
Table 29 North America: Autologous Therapies Market, by Country, 2018-2025 (USD Million)
Table 30 Europe: Autologous Therapies Market, by Country, 2018-2025 (USD Million)
Table 31 APAC: Autologous Therapies Market, by Country, 2018-2025 (USD Million)
6.3.2 Allogeneic Therapies
6.3.2.1 Rising Incidence of Chronic Conditions to Drive the Market Growth
Table 32 Examples of Commercialized Allogeneic Cell Therapies
Table 33 Allogeneic Therapies Market, by Region, 2018-2025 (USD Million)
Table 34 North America: Allogeneic Therapies Market, by Country, 2018-2025 (USD Million)
Table 35 Europe: Allogeneic Therapies Market, by Country, 2018-2025 (USD Million)
Table 36 APAC: Allogeneic Therapies Market, by Country, 2018-2025 (USD Million)
6.4 Gene Therapies
6.4.1 Growing Number of Cancer Cases to Drive Market Growth
Table 37 Examples of Commercialized Gene Therapies
Table 38 Gene Therapies Market, by Region, 2018-2025 (USD Million)
Table 39 North America: Gene Therapies Market, by Country, 2018-2025 (USD Million)
Table 40 Europe: Gene Therapies Market, by Country, 2018-2025 (USD Million)
Table 41 APAC: Gene Therapies Market, by Country, 2018-2025 (USD Million)
6.5 Progenitor & Stem Cell Therapies
6.5.1 Growing Product Pipeline to Support the Growth of this Segment
Table 42 Examples of Commercialized Progenitor & Stem Cell Therapies
Table 43 Progenitor & Stem Cell Therapies Market, by Region, 2018-2025 (USD Million)
Table 44 North America: Progenitor & Stem Cell Therapies Market, by Country, 2018-2025 (USD Million)
Table 45 Europe: Progenitor & Stem Cell Therapies Market, by Country, 2018-2025 (USD Million)
Table 46 APAC: Progenitor & Stem Cell Therapies Market, by Country, 2018-2025 (USD Million)

7 Regenerative Medicine Market, by Application
7.1 Introduction
Table 47 Number of Clinical Trials for Regenerative Medicine Products, by Application, 2018 Vs. 2019
Table 48 Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
7.2 Musculoskeletal Disorders
7.2.1 Increasing Prevalence of Orthopedic Disorders to Drive the Growth of this Application Segment
Table 49 Regenerative Medicine Market for Musculoskeletal Disorders, by Region, 2018-2025 (USD Million)
Table 50 North America: Regenerative Medicine Market for Musculoskeletal Disorders, by Country, 2018-2025 (USD Million)
Table 51 Europe: Regenerative Medicine Market for Musculoskeletal Disorders, by Country, 2018-2025 (USD Million)
Table 52 APAC: Regenerative Medicine Market for Musculoskeletal Disorders, by Country, 2018-2025 (USD Million)
7.3 Oncology
7.3.1 Increasing Incidence of Cancer to Support Market Growth
Table 53 Number of Patients, by Type of Cancer, 2012-2030
Table 54 Indicative List of Few Commercialized Regenerative Cell Therapies for the Treatment of Cancer
Table 55 Regenerative Medicine Market for Oncology, by Region, 2018-2025 (USD Million)
Table 56 North America: Regenerative Medicine Market for Oncology, by Country, 2018-2025 (USD Million)
Table 57 Europe: Regenerative Medicine Market for Oncology, by Country, 2018-2025 (USD Million)
Table 58 APAC: Regenerative Medicine Market for Oncology, by Country, 2018-2025 (USD Million)
7.4 Wound Care
7.4.1 Rising Prevalence of Chronic Conditions to Drive the Growth of this Segment
Table 59 Regenerative Medicine Products Commercialized for the Treatment of Acute & Chronic Wounds
Table 60 Regenerative Medicine Market for Wound Care, by Region, 2018-2025 (USD Million)
Table 61 North America: Regenerative Medicine Market for Wound Care, by Country, 2018-2025 (USD Million)
Table 62 Europe: Regenerative Medicine Market for Wound Care, by Country, 2018-2025 (USD Million)
Table 63 APAC: Regenerative Medicine Market for Wound Care, by Country, 2018-2025 (USD Million)
7.5 Dental
7.5.1 Rising Incidence of Oral Disorders to Drive the Market Growth
Table 64 Regenerative Medicine Market for Dental Applications, by Region, 2018-2025 (USD Million)
Table 65 North America: Regenerative Medicine Market for Dental Applications, by Country, 2018-2025 (USD Million)
Table 66 Europe: Regenerative Medicine Market for Dental Applications, by Country, 2018-2025 (USD Million)
Table 67 APAC: Regenerative Medicine Market for Dental Applications, by Country, 2018-2025 (USD Million)
7.6 Ocular Disorders
7.6.1 Rising Product Approvals to Drive Market Growth
Table 68 Regenerative Medicine Market for Ocular Disorders, by Region, 2018-2025 (USD Million)
Table 69 North America: Regenerative Medicine Market for Ocular Disorders, by Country, 2018-2025 (USD Million)
Table 70 Europe: Regenerative Medicine Market for Ocular Disorders, by Country, 2018-2025 (USD Million)
Table 71 APAC: Regenerative Medicine Market for Ocular Disorders, by Country, 2018-2025 (USD Million)
7.7 Other Applications
Table 72 Regenerative Medicine Market for Other Applications, by Region, 2018-2025 (USD Million)
Table 73 North America: Regenerative Medicine Market for Other Applications, by Country, 2018-2025 (USD Million)
Table 74 Europe: Regenerative Medicine Market for Other Applications, by Country, 2018-2025 (USD Million)
Table 75 APAC: Regenerative Medicine Market for Other Applications, by Country, 2018-2025 (USD Million)

8 Regenerative Medicine Market, by Region
8.1 Introduction
Table 76 Number of Players in the Regenerative Medicine Market, by Region, 2018 Vs. 2019
Table 77 Number of Clinical Trials for Regenerative Medicine, by Region (2019)
Table 78 Regenerative Medicine Market, by Region, 2018-2025 (USD Million)
8.2 North America
Figure 16 North America: Regenerative Medicine Market Snapshot
Table 79 North America: Regenerative Medicine Market, by Country, 2018-2025 (USD Million)
Table 80 North America: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 81 North America: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 82 North America: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.2.1 US
8.2.1.1 Growing Product Pipeline to Drive the Market in the US
Table 83 Products Anticipated for Approvals in the Us in 2020
Table 84 Products Anticipated for Filings in the Us in 2020
Table 85 US: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 86 US: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 87 US: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.2.2 Canada
8.2.2.1 Increasing Investments in R&D to Drive Market Growth
Table 88 Canada: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 89 Canada: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 90 Canada: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.3 Europe
Table 91 Europe: Research Funding Overview (2017)
Table 92 Products Anticipated for Approvals in Europe in 2020
Table 93 Products Anticipated for Filings in Europe in 2020
Table 94 Europe: Regenerative Medicine Market, by Country, 2018-2025 (USD Million)
Table 95 Europe: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 96 Europe: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 97 Europe: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.3.1 UK
8.3.1.1 Rising Prevalence of Chronic Conditions to Drive Market Growth in the UK
Table 98 UK: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 99 UK: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 100 UK: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.3.2 Germany
8.3.2.1 Rising Healthcare Expenditure to Propel Market Growth
Table 101 Germany: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 102 Germany: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 103 Germany: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.3.3 France
8.3.3.1 Rising R&D Expenditure, a Major Growth Driver in France
Table 104 France: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 105 France: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 106 France: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.3.4 Rest of Europe
Table 107 RoE: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 108 RoE: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 109 RoE: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.4 Asia-Pacific
Figure 17 Asia-Pacific: Regenerative Medicine Market Snapshot
Table 110 APAC: Regenerative Medicine Market, by Country, 2018-2025 (USD Million)
Table 111 APAC: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 112 APAC: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 113 APAC: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.4.1 Japan
8.4.1.1 Comparatively Lenient Regulations and Rising Geriatric Population to Drive Market Growth
Table 114 Japan: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 115 Japan: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 116 Japan: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.4.2 China
8.4.2.1 Favorable Investments and Government Support to Drive Market Growth in China
Table 117 China: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 118 China: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 119 China: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.4.3 Australia
8.4.3.1 Strong Research Base and Availability of Funds to Drive Market Growth
Table 120 Australia: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 121 Australia: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 122 Australia: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.4.4 RoAPAC
Table 123 RoAPAC: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 124 RoAPAC: Cell Therapies Market, by Type, 2018-2025 (USD Million)
Table 125 RoAPAC: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)
8.5 Rest of the World
Table 126 RoW: Regenerative Medicine Market, by Product, 2018-2025 (USD Million)
Table 127 RoW: Regenerative Medicine Market, by Application, 2018-2025 (USD Million)

9 Competitive Landscape
9.1 Overview
Figure 18 Key Developments in the Regenerative Medicine Market (January 2017-August 2020)
9.2 Cell Therapy Market Share Analysis
Figure 19 Cell Therapy Market Share Analysis, by Key Player, 2019
9.3 Gene Therapy Market Share Analysis
Figure 20 Gene Therapy Market Share Analysis, by Key Player, 2019
9.4 Tissue Engineering Market Ranking
Figure 21 Tissue Engineering Market Ranking, 2019
9.5 Competitive Scenario
9.5.1 Product Launches & Regulatory Approvals
Table 128 Product Launches & Regulatory Approvals (January 2017-August 2020)
9.5.2 Collaborations
Table 129 Collaborations (January 2017-August 2020)
9.5.3 Acquisitions
Table 130 Acquisitions (January 2017-August 2020)
9.5.4 Expansions
Table 131 Expansions (January 2017-August 2020)

10 Company Evaluation Matrix and Company Profiles
10.1 Company Evaluation Matrix Definition and Methodology
10.1.1 Vendor Inclusion Criteria
10.1.2 Stars
10.1.3 Emerging Leaders
10.1.4 Pervasive
10.1.5 Participants
Figure 22 Regenerative Medicine Market: Competitive Leadership Mapping, 2019
10.2 Company Evaluation Matrix for Start-Ups (2019)
10.2.1 Progressive Companies
10.2.2 Responsive Companies
10.2.3 Starting Blocks
10.2.4 Dynamic Companies
Figure 23 Regenerative Medicine Market: Competitive Leadership Mapping for Start-Ups, 2019
10.3 Company Profiles
(Business Overview, Products Offered, Recent Developments, Analyst's View)*
10.3.1 Smith & Nephew plc
Figure 24 Smith & Nephew plc: Company Snapshot (2019)
10.3.2 Vericel Corporation
Figure 25 Vericel Corporation: Company Snapshot (2019)
10.3.3 Integra Lifesciences Holdings Corporation
Figure 26 Integra Lifesciences Holdings Corporation: Company Snapshot (2019)
10.3.4 Mimedx Group
Figure 27 Mimedx Group: Company Snapshot (2019)
10.3.5 Novartis Ag
Figure 28 Novartis: Company Snapshot (2019)
10.3.6 Stryker Corporation
Figure 29 Stryker Corporation: Company Snapshot (2019)
10.3.7 Organogenesis Inc.
Figure 30 Organogenesis: Company Snapshot (2019)
10.3.8 Medipost Co., Ltd.
Figure 31 Medipost Co., Ltd.: Company Snapshot (2019)
10.3.9 3M Group
Figure 32 3M Group: Company Snapshot (2019)
10.3.10 Misonix
Figure 33 Misonix: Company Snapshot (2019)
10.3.11 Zimmer Biomet
Figure 34 Zimmer Biomet: Company Snapshot (2019)
10.3.12 Medtronic plc
Figure 35 Medtronic plc: Company Snapshot (2019)
10.3.13 Amgen, Inc.
Figure 36 Amgen, Inc.: Company Snapshot (2019)
10.3.14 Allergan
Figure 37 Allergan: Company Snapshot (2019)
10.3.15 Takeda Pharmaceutical Company Limited
Figure 38 Takeda Pharmaceutical Company Limited: Company Snapshot (2019)
10.3.16 Orthocell Ltd.
10.3.17 Tego Science, Inc.
10.3.18 Corestem, Inc.
10.3.19 Anterogen Co., Ltd.
10.3.20 Bluebird Bio
10.3.21 Spark Therapeutics
10.3.22 Kite Pharma
10.3.23 APAC Biotech
10.3.24 Shenzhen Sibiono Genetech Co., Ltd.
10.3.25 Aspect Biosystems

*Business Overview, Products Offered, Recent Developments, Analyst's View Might Not be Captured in Case of Unlisted Companies.

11 Appendix
11.1 Insights from Industry Experts
11.2 Discussion Guide
11.3 Knowledge Store: The Subscription Portal
11.4 Available Customizations

Note: Product cover images may vary from those shown

Loading
LOADING...

  • 3M Group
  • Allergan
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Aspect Biosystems
  • Bluebird Bio
  • Corestem, Inc.
  • Integra Lifesciences Holdings Corporation
  • Kite Pharma
  • Medipost Co., Ltd.
  • Medtronic plc
  • Mimedx Group
  • Misonix
  • Novartis Ag
  • Organogenesis Inc.
  • Orthocell Ltd.
  • Shenzhen Sibiono Genetech Co., Ltd.
  • Smith & Nephew plc
  • Spark Therapeutics
  • Stryker Corporation
  • Takeda Pharmaceutical Company Limited
  • Tego Science, Inc.
  • Vericel Corporation
  • Zimmer Biomet
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll